第三届心血管结局试验（CVOT）峰会报告——糖尿病与心血管疾病（D&CVD）EASD 研究组。
Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.
机构信息
Forschergruppe Diabetes e.V., Munich, Ingolstaedter Landstrasse 1, Neuherberg, 85764, Munich, Germany.
Internal Medicine Department, Clinical County Emergency Hospital Constanta, Tomis Blvd. No. 145, 900591, Constanta, Romania.
出版信息
Cardiovasc Diabetol. 2018 Feb 19;17(1):30. doi: 10.1186/s12933-018-0667-2.
Abstract
The 3rd Cardiovascular Outcome Trial Summit of the Diabetes & Cardiovascular Disease EASD Study Group was held on the 26-27 October 2017 in Munich. As in 2015 and 2016, this summit was organised in light of recently completed and published CVOTs on diabetes, aiming to serve as a reference meeting for in-depth discussions on the topic. Amongst others, the CVOTs EXSCEL, DEVOTE, the CANVAS program and the ACE-trial, which released primary outcome results in 2017, were discussed. Trial implications for diabetes management and recent perspectives of diabetologists, cardiologists, endocrinologists, nephrologists and general practitioners were highlighted. The clinical relevance of cardiovascular outcome trials and its implications regarding reimbursement were compared with real-world studies. The 4th Cardiovascular Outcome Trial Summit will be held in Munich 25-26 October 2018 ( http://www.dcvd.org ).
摘要
第三届糖尿病与心血管疾病 EASD 研究组心血管结局试验峰会于 2017 年 10 月 26 日至 27 日在慕尼黑举行。与 2015 年和 2016 年一样，本次峰会是根据最近完成并发表的糖尿病心血管结局试验组织召开的，旨在为深入讨论该主题提供参考。其中讨论了 EXSCEL、DEVOTE、CANVAS 计划和 ACE 试验，这些试验在 2017 年公布了主要结局结果。还强调了试验对糖尿病管理的影响以及糖尿病专家、心脏病专家、内分泌专家、肾病专家和全科医生的最新观点。心血管结局试验的临床相关性及其与实际研究相比的报销意义进行了比较。第四届心血管结局试验峰会将于 2018 年 10 月 25 日至 26 日在慕尼黑举行（http://www.dcvd.org）。
相似文献
1
Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.第三届心血管结局试验（CVOT）峰会报告——糖尿病与心血管疾病（D&CVD）EASD 研究组。
Cardiovasc Diabetol. 2018 Feb 19;17(1):30. doi: 10.1186/s12933-018-0667-2.
2
Report from the 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.第四届心血管结局试验 (CVOT) 峰会报告：糖尿病与心血管疾病 (D&CVD) EASD 研究组。
Cardiovasc Diabetol. 2019 Mar 11;18(1):30. doi: 10.1186/s12933-019-0822-4.
3
Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group.糖尿病与心血管疾病（D&CVD）欧洲糖尿病研究学会（EASD）研究小组第一次心血管结局试验（CVOT）峰会报告。
Cardiovasc Diabetol. 2016 Feb 18;15:33. doi: 10.1186/s12933-016-0357-x.
4
Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group.糖尿病与心血管疾病（D&CVD）欧洲糖尿病研究学会（EASD）研究组第二届心血管结局试验（CVOT）峰会报告。
Cardiovasc Diabetol. 2017 Mar 11;16(1):35. doi: 10.1186/s12933-017-0508-8.
5
Report from the 5th cardiovascular outcome trial (CVOT) summit.第五届心血管结局试验（CVOT）峰会报告。
Cardiovasc Diabetol. 2020 Apr 17;19(1):47. doi: 10.1186/s12933-020-01022-7.
6
Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.2021 年心血管结局试验峰会报告：心血管、肾脏和血糖结局的新发现。
Cardiovasc Diabetol. 2022 Apr 8;21(1):50. doi: 10.1186/s12933-022-01481-0.
7
Report from the CVOT Summit 2020: new cardiovascular and renal outcomes.2020 年心血管结局试验峰会报告：新的心血管和肾脏结局。
Cardiovasc Diabetol. 2021 Mar 31;20(1):75. doi: 10.1186/s12933-021-01254-1.
8
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes.CVOT 峰会报告 2023：心血管、肾脏和代谢结局的新发现
Cardiovasc Diabetol. 2024 Mar 19;23(1):104. doi: 10.1186/s12933-024-02180-8.
9
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes.CVOT 峰会 2022 报告：心血管、肾脏和血糖结局的新发现。
Cardiovasc Diabetol. 2023 Mar 16;22(1):59. doi: 10.1186/s12933-023-01788-6.
10
Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG).将心血管结局试验的最新结果转化为临床实践：来自中欧和东欧糖尿病专家组（CEEDEG）的建议。
Cardiovasc Diabetol. 2017 Oct 23;16(1):137. doi: 10.1186/s12933-017-0622-7.
引用本文的文献
1
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes.2024年心血管结局试验峰会报告：新的心血管、肾脏及代谢结局
Cardiovasc Diabetol. 2025 May 2;24(1):187. doi: 10.1186/s12933-025-02700-0.
2
The potential of precision diabetology for type 2 diabetes treatment-evidence from a meta-regression for all-cause mortality from large cardiovascular outcome trials.精准糖尿病学在2型糖尿病治疗中的潜力——来自大型心血管结局试验全因死亡率Meta回归分析的证据
Acta Diabetol. 2024 Dec 12. doi: 10.1007/s00592-024-02425-8.
3
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes.CVOT 峰会报告 2023：心血管、肾脏和代谢结局的新发现
Cardiovasc Diabetol. 2024 Mar 19;23(1):104. doi: 10.1186/s12933-024-02180-8.
4
Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data.新型抗糖尿病药物对复合肾脏结局的绝对治疗效果：数字化个体患者数据的荟萃分析
J Nephrol. 2024 Mar;37(2):309-321. doi: 10.1007/s40620-023-01858-8. Epub 2024 Jan 18.
5
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes.CVOT 峰会 2022 报告：心血管、肾脏和血糖结局的新发现。
Cardiovasc Diabetol. 2023 Mar 16;22(1):59. doi: 10.1186/s12933-023-01788-6.
6
Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.2021 年心血管结局试验峰会报告：心血管、肾脏和血糖结局的新发现。
Cardiovasc Diabetol. 2022 Apr 8;21(1):50. doi: 10.1186/s12933-022-01481-0.
7
Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis.2型糖尿病合并心血管疾病患者使用恩格列净与其他降糖药物的医疗成本和资源利用情况：一项真实世界回顾性队列分析
Diabetes Ther. 2022 Jan;13(1):25-42. doi: 10.1007/s13300-021-01173-0. Epub 2021 Nov 2.
8
Changing the approach to type 2 diabetes treatment: A comparison of glucagon-like peptide-1 receptor agonists and sulphonylureas across the continuum of care.改变 2 型糖尿病治疗方法：在整个治疗过程中比较胰高血糖素样肽-1 受体激动剂和磺脲类药物。
Diabetes Metab Res Rev. 2021 Oct;37(7):e3434. doi: 10.1002/dmrr.3434. Epub 2021 Feb 7.
9
Report from the CVOT Summit 2020: new cardiovascular and renal outcomes.2020 年心血管结局试验峰会报告：新的心血管和肾脏结局。
Cardiovasc Diabetol. 2021 Mar 31;20(1):75. doi: 10.1186/s12933-021-01254-1.
10
Report from the 5th cardiovascular outcome trial (CVOT) summit.第五届心血管结局试验（CVOT）峰会报告。
Cardiovasc Diabetol. 2020 Apr 17;19(1):47. doi: 10.1186/s12933-020-01022-7.
本文引用的文献
1
Updates on cardiovascular outcome trials in diabetes.糖尿病心血管结局试验的最新进展。
Cardiovasc Diabetol. 2017 Oct 11;16(1):128. doi: 10.1186/s12933-017-0610-y.
2
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.阿卡波糖对冠心病合并糖耐量受损患者心血管和糖尿病结局的影响（ACE）：一项随机、双盲、安慰剂对照试验。
Lancet Diabetes Endocrinol. 2017 Nov;5(11):877-886. doi: 10.1016/S2213-8587(17)30309-1. Epub 2017 Sep 13.
3
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.每周一次艾塞那肽对2型糖尿病患者心血管结局的影响。
N Engl J Med. 2017 Sep 28;377(13):1228-1239. doi: 10.1056/NEJMoa1612917. Epub 2017 Sep 14.
4
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.载脂蛋白 AI 模拟肽（Anacetrapib）在动脉粥样硬化性血管疾病患者中的作用。
N Engl J Med. 2017 Sep 28;377(13):1217-1227. doi: 10.1056/NEJMoa1706444. Epub 2017 Aug 28.
5
Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes.理解 GLP-1RA 和 DPP-4 治疗药物在 2 型糖尿病患者中的随机对照试验疗效与真实世界应用效果之间的差距。
Diabetes Care. 2017 Nov;40(11):1469-1478. doi: 10.2337/dc16-2725. Epub 2017 Aug 11.
6
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.卡格列净与 2 型糖尿病的心血管和肾脏事件。
N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
7
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.德谷胰岛素与甘精胰岛素治疗2型糖尿病的疗效和安全性比较
N Engl J Med. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12.
8
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).与其他降糖药物相比，起始使用钠-葡萄糖协同转运蛋白2抑制剂的患者发生心力衰竭和死亡的风险更低：CVD-REAL研究（钠-葡萄糖协同转运蛋白2抑制剂新使用者心血管结局的比较有效性）
Circulation. 2017 Jul 18;136(3):249-259. doi: 10.1161/CIRCULATIONAHA.117.029190. Epub 2017 May 18.
9
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.依洛尤单抗与心血管疾病患者的临床结局。
N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.
10
Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group.糖尿病与心血管疾病（D&CVD）欧洲糖尿病研究学会（EASD）研究组第二届心血管结局试验（CVOT）峰会报告。
Cardiovasc Diabetol. 2017 Mar 11;16(1):35. doi: 10.1186/s12933-017-0508-8.
Zotero 插件